P E Palumbo
Affiliation: New Jersey
- Pediatric HIV infection and treatmentPaul Palumbo
Department of Pediatrics, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
Clin Lab Med 22:759-72. 2002..Significant questions remain and have been largely refocused to the complexities of a chronic disease process. Management invariably requires specialists who must keep abreast of a rapidly evolving information base...
- Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and childrenP E Palumbo
Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
J Infect Dis 179:576-83. 1999..Nevertheless, plasma RNA and CD4 lymphocyte count together possess strong clinical predictive power and are valuable tools for both the clinician and the evaluation of new therapies...
- Antiretroviral therapy of HIV infection in childrenP E Palumbo
Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
Pediatr Clin North Am 47:155-69. 2000..Efforts are ongoing to develop simpler, more effective therapeutic regimens that suppress and ultimately eradicate infection and that stimulate immune reconstitution...
- Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and cladesP Palumbo
Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA
J Infect Dis 184:1120-6. 2001..Although no effect of viral resistance on mother-infant transmission was demonstrated, the advent of more-potent drug classes and the potential for the rapid emergence of resistance warrant prospective surveillance...
- Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and childrenP E Palumbo
Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark 07103, USA
JAMA 279:756-61. 1998..Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis...
- Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infectionPaul Palumbo
Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
J Infect Dis 196:23-9. 2007..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches...
- Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposureJoan H Skurnick
Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark, NJ 07103 2714, USA
J Infect Dis 185:428-38. 2002..These observations suggest that the primary protective factor is CD8 cell activity in both the HIV-positive donor and the HIV-negative partner. These findings have substantial implications for vaccine development...
- Quantitative RNA testing for diagnosis of HIV-infected infantsSteven Nesheim
Emory University School of Medicine, Department of Pediatrics, Infectious Diseases, Epidemiology and Immunology, 69 Butler Street SE, Atlanta, GA 30335, USA
J Acquir Immune Defic Syndr 32:192-5. 2003..Quantitative RNA testing can be used for diagnosis in HIV-exposed infants, recognizing the chance for a false-positive test result. It may be most useful as a confirmatory test in infants with another positive diagnostic test result...
- Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United StatesDeborah Persaud
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
J Infect Dis 195:1402-10. 2007....
- Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1Paul Krogstad
Department of Pediatrics, University of California Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
AIDS Res Hum Retroviruses 18:413-7. 2002..Non-B subtypes should be considered in the management of HIV-1-infected pregnant women and children to optimize strategies to prevent and treat pediatric HIV-1 infection...
- CD4/CD8 T-cell ratio predicts HIV infection in infants: the National Heart, Lung, and Blood Institute P2C2 StudyWilliam T Shearer
Department of Pediatrics, Section of Allergy and Immunology, Baylor College of Medicine, Houston, TX, USA
J Allergy Clin Immunol 120:1449-56. 2007..In resource-poor regions of the world, HIV virologic testing is not available...
- Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week resultsEllen G Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
AIDS 22:249-55. 2008..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
- Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyEllen Gould Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Pediatr Infect Dis J 28:215-9. 2009....
- Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5AMainul Hoque
Department of Biochemistry and Molecular Biology, UMDNJ New Jersey Medical School, NJ 07103, USA
Retrovirology 6:90. 2009..DOHH activity is inhibited by two clinically used drugs, the topical fungicide ciclopirox and the systemic medicinal iron chelator deferiprone. Deferiprone has been reported to inhibit HIV-1 replication in tissue culture...
- Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 productionNeerja Kaushik
Center for the Study of Emerging and Re Emerging Pathogens, UMDNJ New Jersey Medical School, Newark, New Jersey 07103, USA
J Virol 76:3881-91. 2002..The mechanism of this inhibition appeared to be regulated at the level of transcription. These results demonstrate the efficacy of PNA(TAR)-transportan as a potential anti-HIV agent...
- Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatmentAdriana Weinberg
Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
J Acquir Immune Defic Syndr 52:17-24. 2009..We sought to identify the immunologic and virologic factors associated with a robust response to hepatitis A virus (HAV) vaccine in children on highly active antiretroviral treatment...
- Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected childrenJoseph A Church
Department of Pediatrics, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, 90027, USA
Pediatr Infect Dis J 21:653-9. 2002..The fusion inhibitor T-20 is the first in this new class, and the present study is the first to examine chronic s.c. administration of T-20 to HIV-1-infected children...
- Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004Steven R Nesheim
Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
Pediatrics 120:100-9. 2007..We sought to determine the impact of highly active antiretroviral therapy on the incidence and prevalence of opportunistic infections in HIV-infected children...
- Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004)Bill G Kapogiannis
Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
Pediatrics 121:e1229-39. 2008..Highly active antiretroviral therapy has reduced rates of opportunistic infections; less is known about its effect on pediatric bacteremia rates. Thus, we sought to determine its impact on bacteremia incidence in HIV-infected children...
- Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitorsJanet A Englund
University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
Pediatr Infect Dis J 23:15-22. 2004..We evaluated the development of antiretroviral genotypic resistance and clinical outcome in a subgroup of children involved in a prospective antiretroviral therapy trial (Pediatric AIDS Clinical Trials Group Protocol 152)...
- Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infectionJohan K Sandberg
Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
J Virol 76:7528-34. 2002..These data indicate that the key immunoregulatory NKT-cell compartment is compromised in HIV-1-infected patients...
- Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in childrenElaine J Abrams
Harlem Hospital Center and Columbia University, College of Physicians and Surgeons, New York, New York 10037, USA
AIDS 17:867-77. 2003..To determine the relationship of maternal health factors and infant antiretroviral treatment to the risk of pediatric disease progression to AIDS or death by 24 months of age...
- The time to treat the children is nowLisa V Adams
J Infect Dis 195:1396-8. 2007
- Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocolSusan Schuval
Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
Arch Pediatr Adolesc Med 158:1007-13. 2004..To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection...
- Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progressionLouise Kuhn
Gertrude H Sergievsky Center, College of Physicians and Surgeons, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
AIDS 18:1281-9. 2004..We investigated whether maternal HLA selection pressures on the virus would adversely influence clinical outcomes of HIV-infected children...
- Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected childrenJoseph A Church
Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
Pediatr Infect Dis J 23:713-8. 2004..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide...
- Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationshipsDolors Soy
Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, Calif, USA
Clin Pharmacol Ther 74:569-80. 2003..Our objective was to describe the population pharmacokinetics and pharmacodynamics of enfuvirtide acting on viral ribonucleic acid in children with human immunodeficiency virus 1...
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsE V Capparelli
San Diego Schools of Medicine and Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92103, USA
HIV Med 9:214-20. 2008..To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population...
- GB virus C infection in children with perinatal human immunodeficiency virus infectionSusan Schuval
Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
Pediatr Infect Dis J 24:417-22. 2005..GB virus C (GBV-C) infection occurs in 20-40% of human immunodeficiency virus (HIV)-infected adults, and coinfection is associated with improved HIV disease outcome...
- Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of ageEllen Gould Chadwick
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Pediatr Infect Dis J 24:793-800. 2005..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age...
- Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysisRosalind J Carter
Medical and Health Research Association, New York, NY 10032, USA
J Acquir Immune Defic Syndr 41:453-60. 2006..Protease inhibitor (PI)-containing regimens have led to improved survival among HIV-infected children. However, adverse effects, including dyslipidemia, may put children at risk for cardiovascular disease...
- Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and childrenEdmund V Capparelli
University of California, San Diego, School of Medicine, La Jolla, California, USA
J Clin Pharmacol 43:133-40. 2003..It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity...
- Challenges to re-enrolling perinatally HIV-infected and HIV-exposed but uninfected children into a prospective cohort study: strategies for locating and recruiting hard-to-reach familiesDarcy Freedman
U S Centers for Disease Control and Prevention, National Center for HIV STD TB Prevention, Atlanta, GA, USA
Paediatr Perinat Epidemiol 20:338-47. 2006..The PACTS-HOPE cohort will provide opportunities for future research aimed at understanding the unique effects of HIV on the well-being of HIV-infected children...
- Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)William T Shearer
J Allergy Clin Immunol 118:518-21. 2006
- Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected childrenCourtney V Fletcher
J Allergy Clin Immunol 119:747-50. 2007